^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    sturlimogene erparepvec (RP2)

    i
    Other names: RP2
    Associations

    News

    Trials
    Company:
    Replimune
    Drug class:
    CTLA4 inhibitor, G-CSF stimulant
    Related drugs:
    Associations

    News

    Trials
    2ms
    RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, City of Hope Medical Center
    New P2 trial
    |
    Fotivda (tivozanib) • sturlimogene erparepvec (RP2)
    3ms
    Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC (clinicaltrials.gov)
    P2, N=60, Recruiting, Replimune Inc. | N=30 --> 60
    Enrollment change
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • sturlimogene erparepvec (RP2)
    4ms
    RPx: A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Replimune Inc. | Initiation date: Jun 2025 --> Nov 2025
    Trial initiation date
    |
    RP3 • Tudriqev (vusolimogene oderparepvec-wtpg) • sturlimogene erparepvec (RP2)
    5ms
    Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Abramson Cancer Center at Penn Medicine
    New P2 trial
    |
    docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • sturlimogene erparepvec (RP2)
    9ms
    RPx: A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Replimune Inc.
    New trial
    |
    RP3 • Tudriqev (vusolimogene oderparepvec-wtpg) • sturlimogene erparepvec (RP2)
    1year
    RP2-202: A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma (clinicaltrials.gov)
    P2/3, N=280, Recruiting, Replimune Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Checkpoint inhibition • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • sturlimogene erparepvec (RP2)
    1year
    Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC (clinicaltrials.gov)
    P2, N=30, Recruiting, Replimune Inc. | Not yet recruiting --> Recruiting | N=60 --> 30 | Trial completion date: Jul 2027 --> Jul 2028 | Trial primary completion date: Apr 2027 --> Dec 2027
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Oncolytic virus • Metastases
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • sturlimogene erparepvec (RP2)
    over1year
    RP2-202: A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma (clinicaltrials.gov)
    P2/3, N=280, Not yet recruiting, Replimune Inc.
    New P2/3 trial • Combination therapy • Checkpoint inhibition • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • sturlimogene erparepvec (RP2)
    over1year
    RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC (clinicaltrials.gov)
    P2, N=4, Active, not recruiting, Replimune Inc. | N=60 --> 4
    Enrollment change • Combination therapy • Oncolytic virus • Mismatch repair • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • RP3 • sturlimogene erparepvec (RP2)
    almost2years
    RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Replimune Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Oncolytic virus • Mismatch repair • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • RP3 • sturlimogene erparepvec (RP2)
    almost2years
    An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab plus bevacizumab for the treatment of patients with advanced colorectal carcinoma. (ASCO-GI 2024)
    Safety will be assessed by physical examination, clinical laboratory evaluations, vital signs, and monitoring for adverse events (AEs; including serious AEs). Clinical trial information: NCT05733611.
    Clinical • Combination therapy • Oncolytic virus • Metastases
    |
    MSI (Microsatellite instability) • CD40 (CD40 Molecule)
    |
    MSI-H/dMMR • CSF2 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • RP3 • sturlimogene erparepvec (RP2)
    over2years
    RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC (clinicaltrials.gov)
    P2, N=60, Recruiting, Replimune Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Oncolytic virus • Mismatch repair • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • RP3 • sturlimogene erparepvec (RP2)